SKYEPHARMA PLC
Form 6-K
June 11, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2003

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
_____

For Immediate Release: **11 Ju**

BSKYEPHARMA RESEARCH & DEVELOPMENT DAY

New Data on DepoMorphine and Propofol IDD-D to be Presented

LONDON, ENGLAND, June 11, 2003 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) is today presenting an its Research and Development programmes. The presentation provides institutional shareholders and analysts with an update on the Group's extensive product pipeline and features clinical developme its lead pipeline products, DepoMorphine and Propofol IDD-D, as well as details of the product po including both internally developed products and those developed for SkyePharma's clients.

The presentation begins with a brief introduction by Michael Ashton, SkyePharma's Chief Executive who provides an overview on the Group's major marketed products: Paxil CR, a controlled-release v GlaxoSmithKline's antidepressant Paxil; Solaraze for actinic keratosis (marketed by Quintiles Tra in North America and by Shire Pharmaceuticals in Europe); Xatral OD, a once-daily version of Sano Xatral for urinary difficulties associated with benign prostatic hypertrophy; and Depocyt, a cont injectable formulation of cytarabine for lymphomatous meningitis, marketed in North America by En

This is followed by a series of presentations from SkyePharma's senior management.

- **New Phase III trial data on DepoMorphine to be presented.**

SkyePharma's novel controlled-release injectable formulation of morphine for control of post-oper DepoMorphine, is given as a single epidural injection before surgery and provides highly effectiv 48 hours, the period of peak pain after an operation. By contrast conventional morphine only prov for up to 12 hours and repeat administration normally requires catheters and infusion pumps that source of problems. Dr Gordon Schooley, head of clinical development for SkyePharma, reviews the programme for DepoMorphine which involved four separate pain models involving nearly 1000 patient trials, in hip surgery and lower abdominal surgery, DepoMorphine demonstrated sustained dose-rela achieved its primary endpoint (superiority over study comparators in terms of total demand for op surgery) with a high degree of statistical significance. DepoMorphine also achieved statistical s several secondary endpoints such as patient perception of pain intensity and adequacy of pain rel Phase IIb trials, DepoMorphine was significantly better than study comparators in the caesarean s approached statistical significance in the knee arthroplasty study. In the latter study, the prim recalled pain intensity. DepoMorphine did achieve a high degree of statistical significance in to opioid analgesics after surgery, a secondary endpoint in this trial but the primary endpoint in t SkyePharma expects to file DepoMorphine with the FDA around the middle of this year and with the September. DepoMorphine was licensed to Endo Pharmaceuticals for North America at the end of 2002 to appoint licensees in other territories this year.

- **New Phase II clinical data Propofol IDD-D 2%, a new proprietary formulation of the injectable anaesthetic and sedative propofol.**

The global market for AstraZeneca's Diprivan and some generic versions was $650 mn in 2002. The S cannot support microbial growth, a recognized problem with current versions that requires opened tubing to be disposed of after 8-12 hours. Propofol IDD-D 2% should provide uninterrupted sedatio the need for preservatives and reduces the risks of hyperlipidemia and fluid overload associated of propofol. In the recently completed Phase II trial, the SkyePharma version was shown to be sim terms of pharmacokinetics, anaesthetic efficacy and safety. Propofol IDD-D 2% will commence Phase over 700 patients, by the end of 2003. Propofol IDD-D 2% was licensed to Endo Pharmaceuticals for end of 2002. SkyePharma expects to appoint licensees in other territories later this year.

This is followed by an overview of SkyePharma's pulmonary product pipeline. This includes a dry-p of Novartis' bronchodilator Foradil which was filed with the FDA and European authorities in Dece Dr Niederlander, head of SkyePharma's pulmonary unit in Basel, Switzerland, also reviews an HFA a of formoterol (due to enter Phase III trials later this year); an HFA aerosol inhaler version of (AstraZeneca's Pulmicort) which will also enter Phase III trials later this year; and an HFA aero a fixed dose combination of formoterol and fluticasone (to move into Phase II development in the

Dr Richard Jones, head of R&D, will then present SkyePharma's controlled-release injectable deliv DepoFoam and Biosphere and their application to the delivery of biologics. Protein drugs do not s system and so cannot be taken orally but injections are unpopular with patients. SkyePharma's two delivery technologies reduce injection frequency and provide scope for improved products that ove limitations of current protein drugs. Proof of principle has recently been published and SkyePhar negotiations with various potential partners.

Dr Paul Wotton, SKP's head of Business Development, presents an outline of the company's Business
and CEO Michael Ashton concludes with a summing up.

The presentation will commence at 09.45 a.m. BST at Salters Hall, Fore Street, London, EC2Y 5DE. This meeting will be webcast live on www.skyepharma.com.

On Thursday, June 12th, SkyePharma will also host a lunch presentation in New York for its U.S. audience at the St. Regis Hotel, 2 East 55th Street at 5th Avenue, commencing at 11.45 a.m EDT.

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery techn
easier-to-use and more effective drug formulations. There are now nine approved products incorpor
SkyePharma's five delivery technologies in the areas of oral, injectable, inhaled and topical del
advanced solubilisation capabilities. SkyePharma has two FDA- and EMA-approved manufacturing plan
USA, and Lyon, France. For more information, visit www.skyepharma.com

For further information please contact:

SkyePharma Plc + 44 (0) 207
Peter Laing, Director of Corporate Communications

US Investor Relations + 1 (212)
Sandra Haughton

Buchanan Communications +44 (0) 207
Tim Anderson / Nicola How

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: June 11, 2003